Directorate Change

Proteome Sciences PLC
13 May 2003



                 PROTEOME SCIENCES APPOINTS DR. SANDRA STEINER

                                AS R&D DIRECTOR



For immediate release                                             13th May 2003



Proteome Sciences plc (Proteome Sciences) is pleased to announce that Dr. Sandra
Steiner has been appointed to the Board as Research and Development Director
with immediate effect. She will be based at the Company's head office in Cobham,
Surrey, UK.


Dr. Steiner was Executive Vice President of Proteomics at Large Scale Biology
Corporation, Germantown, US (LSBC) until this announcement, having previously
been the founder and Head of Molecular Toxicology/Pharmacogenomics at Novartis
Pharma AG Basel in the period between 1992 and 1998. Prior to that, she worked
at Ciba-Geigy AG and Shell Research Limited.


At LSBC, she was responsible for developing and managing proteomics programmes
and collaborations with industry, academia and government as well as providing
scientific and strategic leadership for the business unit at LSBC Proteomics.
This also involved the establishment of mass spectrometry and protein chemistry
departments in addition to the expansion and automation of protein separation
activities.


This important appointment has been made to allow Proteome Sciences to respond
to the growing development, licensing and commercialisation interest that is
being generated. This is a direct result of highly specific and sensitive
protein markers identified by the Company in major disease areas, in particular
stroke, nvCJD, BSE, neurodegenerative, cancer, transplant rejection,
cardiovascular and diabetes/obesity and the development of protein sequence tag
technology (PSTTM, TMTTM, SensitizerTM) following the acquisition of the Aventis
proteomics facility in Frankfurt in 2002.


Since December 2002 Proteome Sciences has announced two significant licensing
deals for biomarkers in blood, one in the field of stroke with BioSite Inc and
the other for the diagnosis of BSE in live cattle and TSEs in other animals with
IDEXX Laboratories, Inc.


Commenting on her appointment, Dr. Steiner said:


'This role provides an exciting opportunity to exploit the unique tool kit that
Proteome Sciences has developed through its proteomic expertise in diseases and
to accelerate the development and application of the technology platform through
a broad range of strategic commercial partners.


'Using a combination of this technology and commercial alliances, proteomics
will be recognised as a key driver to unlock real value from functional genomics
and through its ability to develop new and improved diagnostic, prognostic and
therapeutic products.'


Christopher Pearce, Chief Executive of Proteome Sciences added:


'Dr. Steiner's knowledge and expertise gained from her positions both from big
pharma and biotechnology will add considerable value and strength to enable us
to further develop and commercialise the technology platforms at Proteome
Sciences, and to bring additional skills among others in toxicology and
toxicoproteomics.


'We are delighted to have someone with Dr. Steiner's international reputation
and profile join us at this highly active growth phase of our corporate and
commercial development.'

                                    - Ends -


For further information please contact:

Proteome Sciences plc

www.proteome.co.uk

Christopher Pearce, Chief Executive     Tel:     [phone]

e-mail:     [e-mail]

Public Relations for Proteome Sciences

Ikon Associates

Adrian Shaw      Tel:      [phone]

Mobile:     [phone]

e-mail:     [e-mail]



Notes to Editors:

Proteome Sciences plc applies high sensitivity proteomics to identify and
characterise differential protein expression in diseases for diagnostic,
prognostic and therapeutic applications. It has to date developed sensitive
blood assays for stroke, nvCJD, BSE and solid organ transplant rejection.


The main focus of its research currently addresses neurological,
neurodegenerative, diabetes/obesity, oncology and cardiovascular conditions.
Commercialisation of these programmes will be effected through strategic
alliances and licensing agreements.


Proteome Sciences is headquartered in Cobham, Surrey in the UK and has
laboratories at Kings College Hospital, London and in Frankfurt. It employs 40
full time scientists in addition to its corporate and business development
staff. The Company has been listed on the Alternative Investment Market since
1994.


                      This information is provided by RNS
            The company news service from the London Stock Exchange